Companies
- Companies
- Company details
Action Pharma A/S
Out-licensing
Phase I Clinical Development of AP 405 for the Treatment of Atopic Dermatitis More
Phase I Clinical Development of AP1030 as an Oral Treatment for Diabetes Type II Associated with Obesity More
Phase I Clinical Development of AP1189: Targeting Inflammatory Bowel Disease and Rheumatoid Arthritis More
Phase II Clinical Development of AP214 for Post-Surgical Kidney Protection after Cardiac Surgery More
Related Reports
Market Research Reports provided by reports.iptechex.com
Dec 2010 - 12 pages - $99
Nov 2010 - 15 pages - $99
Sep 2010 - 14 pages - $99
Jun 2011 - 30 pages - $500
Nov 2010 - 36 pages - $500
Apr 2011 - 38 pages - $500
Apr 2011 - 5 pages - $100
Oct 2011 - 39 pages - $500
Aug 2010 - 25 pages - $99
Apr 2010 - 23 pages - $99
Contact details
Head office
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us